Novartis Aktie

Novartis für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 907122 / ISIN: US66987V1098

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
17.07.2025 07:35:35

Novartis Q2 Profit Rises,lifts FY Core Operating Profit Growth View; Initiates $10 Bln Share Buyback

(RTTNews) - Swiss drug major Novartis AG (NVS) reported that its net income attributable to shareholders for the second quarter rose to $4.041 billion or $2.06 per share from last year's $3.246 billion or $1.59 per share, mainly driven by higher operating income, partly offset by higher net financial expense.

The company is initiating a share buyback program of up to US$10 billion, with completion expected by the end of 2027.

Looking ahead, the company now expects core operating income for fiscal year 2025 to grow in the low teens compared to the prior year, revising its earlier outlook of low double-digit growth. Annual sales are still expected to grow high single digit from the prior year. The outlook reflects growth compared to the prior year on a constant currency basis.

Novartis's core net income attributable to shareholders for the quarter was $4.709 billion or $2.42 per basic share up from $4.008 billion or $1.97 per basic share in the previous year.

Net sales to third parties for the second quarter increased to $14.054 billion from $12.512 billion last year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

Analysen zu Novartis AG (Spons. ADRS)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Novartis AG (Spons. ADRS) 104,00 0,48% Novartis AG (Spons. ADRS)